中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 4
Apr.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(4): 804-809

Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2023.04.010

  • Department of Hepatology, The First Hospital of Jilin University, Changchun 130000, China

Research funding:

National Natural Science Foundation of China (81270484)

More Information
  • Corresponding author: JIN Qinglong, jinql@jlu.edu.cn(ORCID: 0000-0002-4626-9828)
  • Received Date: 2022-09-07
  • Accepted Date: 2022-10-24
  • Published Date: 2023-04-20
    Abstract
  •   Objective  To investigate the effect of Compound Lingdan Capsule on serum biochemical parameters and liver fibrosis degree in a mouse model of liver fibrosis.  Methods  A total of 125 specific pathogen-free male C57BL/6 mice were randomly divided into normal control group with 5 mice, CCl4 model group with 15 mice, low-, middle-, and high-dose CCl4 groups (0.8, 1.6, and 3.2 mg·g-1·d-1) with 15 mice in each group, DDC model group with 15 mice, and low-, middle-, and high-dose DDC groups (0.8, 1.6, and 3.2 mg·g-1·d-1) with 15 mice in each group. After successful modeling, the mice in the administration groups were given Compound Lingdan Capsule suspension at the respective doses by gavage, and those in the normal control group and the model group were given an equal volume of normal saline by gavage, for 4 consecutive weeks. Blood samples were collected from the eyeballs, and serum was used to measure aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, and bilirubin. Liver tissue samples were collected at the same site of the right lobe of the liver for pathological observation, Sirius Red staining, α-SMA antibody staining, and COL1A1 antibody staining. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the Bonferroni method was used for further comparison between two groups.  Results  Compared with the model group, each dose group had significant reductions in the serum level of ALT and a significant increase in the serum level of albumin after the administration of Compound Lingdan Capsule (all P < 0.05), the levels of AST and bilirubin in the middle and high dose groups were lower (all P < 0.05), and the difference of each index in the high dose group was more significant than that in the low dose group (all P < 0.05). Each dose group had varying degrees of improvement in the pathological changes of the liver and a significant reduction in the number of Sirius Red staining-positive cells, as well as varying degrees of reduction in the protein expression of α-SMA and COL1A1.  Conclusion  Compound Lingdan Capsule can improve liver function and reduce liver fibrosis degree in mice with liver fibrosis.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    FRIEDMAN SL. Liver fibrosis-from bench to bedside[J]. J Hepatol, 2003, 38(Suppl 1): S38-S53. DOI: 10.1016/s0168-8278(02)00429-4.
    [2]
    KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7.
    [3]
    WEISKIRCHEN R, WEISKIRCHEN S, TACKE F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts[J]. F1000Res, 2018, 7: F1000 Faculty Rev-921. DOI: 10.12688/f1000research.14841.1.
    [4]
    DU WT, REN WL, HU DD, et al. Research progress on reversible animal model of liver fibrosis[J/CD]. Chin J Liver Dis (Electronic Version), 2022, 14(3): 18-21. DOI: 10.3969/j.issn.1674-7380.2022.03.005.

    杜文涛, 任万雷, 胡豆豆, 等. 肝纤维化可逆转动物模型研究进展[J/CD]. 中国肝脏病杂志(电子版), 2022, 14(3): 18-21. DOI: 10.3969/j.issn.1674-7380.2022.03.005.
    [5]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis (2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
    [6]
    Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.

    中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
    [7]
    PAROLA M, PINZANI M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55. DOI: 10.1016/j.mam.2018.09.002.
    [8]
    LAI M, AFDHAL NH. Liver fibrosis determination[J]. Gastroenterol Clin North Am, 2019, 48(2): 281-289. DOI: 10.1016/j.gtc.2019.02.002.
    [9]
    HAMMEL P, COUVELARD A, O'TOOLE D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct[J]. N Engl J Med, 2001, 344(6): 418-423. DOI: 10.1056/NEJM200102083440604.
    [10]
    ARTHUR MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C[J]. Gastroenterology, 2002, 122(5): 1525-1528. DOI: 10.1053/gast.2002.33367.
    [11]
    KWEON YO, GOODMAN ZD, DIENSTAG JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B[J]. J Hepatol, 2001, 35(6): 749-755. DOI: 10.1016/s0168-8278(01)00218-5.
    [12]
    DIXON JB, BHATHAL PS, HUGHES NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss[J]. Hepatology, 2004, 39(6): 1647-1654. DOI: 10.1002/hep.20251.
    [13]
    CZAJA AJ, CARPENTER HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis[J]. J Hepatol, 2004, 40(4): 646-652. DOI: 10.1016/j.jhep.2004.01.009.
    [14]
    ZHANG Y, LYU WL. Visual analysis of traditional Chinese medicine in the treatment of hepatic fibrosis based on CiteSpace[J]. China Med Herald, 2022, 19(19): 129-132, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202219026.htm

    张亚, 吕文良. 基于CiteSpace中医药治疗肝纤维化的可视化分析[J]. 中国医药导报, 2022, 19(19): 129-132, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202219026.htm
    [15]
    WANG HY, NIU JQ, ZHANG WY, et al. Experimental study on the anti-hepatic fibrosis effect of Compound Lingdan Capsule[J]. Chin Traditional Patent Med, 2014, 36(1): 168-171. DOI: 10.3969/j.issn.1001-1528.2014.01.042.

    王化宇, 牛俊奇, 张炜煜, 等. 复方灵丹胶囊抗肝纤维化作用的实验研究[J]. 中成药, 2014, 36(1): 168-171. DOI: 10.3969/j.issn.1001-1528.2014.01.042.
    [16]
    FALLOWFIELD JA, MIZUNO M, KENDALL TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis[J]. J Immunol, 2007, 178(8): 5288-5295. DOI: 10.4049/jimmunol.178.8.5288.
    [17]
    DOOLEY S, DELVOUX B, STRECKERT M, et al. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells[J]. FEBS Lett, 2001, 502(1-2): 4-10. DOI: 10.1016/s0014-5793(01)02656-4.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (391) PDF downloads(46) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return